Sabet Yasmin, Ramirez Saul, Rosell Cespedes Elizabeth, Rensoli Velasquez Marimer, Porres-Muñoz Mateo, Gaur Sumit, Figueroa-Casas Juan B, Porres-Aguilar Mateo
Division of General Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
Division of Medical Education, Paul L. Foster School of Medicine and Texas Tech University HSC, El Paso, TX 79905, USA.
Case Rep Pulmonol. 2016;2016:2359437. doi: 10.1155/2016/2359437. Epub 2016 Apr 17.
Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially fatal. We report the case of a twenty-nine-year-old female with Hodgkin's lymphoma who was treated with brentuximab and later presented with severe acute pulmonary toxicity; she improved after the discontinuation of brentuximab and administration of antibiotics and glucocorticoid therapy. Currently there is very little data in the literature in regard to the clinical manifestations and characteristics of patients taking brentuximab and the potential development of acute severe pulmonary toxicity, as well as the appropriate therapeutic approach, making this particular case of successful treatment and resolution unique.
与本妥昔单抗相关的急性肺毒性似乎是一种罕见但严重的不良反应,可能会致命。我们报告了一例29岁患有霍奇金淋巴瘤的女性患者,她接受了本妥昔单抗治疗,随后出现了严重的急性肺毒性;在停用本妥昔单抗并给予抗生素和糖皮质激素治疗后,她的病情有所改善。目前,关于服用本妥昔单抗患者的临床表现和特征、急性严重肺毒性的潜在发展以及适当的治疗方法,文献中的数据非常少,使得这一成功治疗和解决的特殊病例显得独一无二。